Three 1 mL doses of Rabies vaccine and two JE vaccine + Three 0.5 mL doses of Rabies vaccine and two JE vaccine + Three 0.1mL doses of Rabies Vaccine and two JE vaccine + Two 0.1mL doses of Rabies vaccine and two JE vaccine + Two doses of JE vaccine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rabies
Conditions
Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis
Trial Timeline
Aug 1, 2002 → Sep 1, 2004
NCT ID
NCT00694460About Three 1 mL doses of Rabies vaccine and two JE vaccine + Three 0.5 mL doses of Rabies vaccine and two JE vaccine + Three 0.1mL doses of Rabies Vaccine and two JE vaccine + Two 0.1mL doses of Rabies vaccine and two JE vaccine + Two doses of JE vaccine
Three 1 mL doses of Rabies vaccine and two JE vaccine + Three 0.5 mL doses of Rabies vaccine and two JE vaccine + Three 0.1mL doses of Rabies Vaccine and two JE vaccine + Two 0.1mL doses of Rabies vaccine and two JE vaccine + Two doses of JE vaccine is a phase 2 stage product being developed by Novartis for Rabies. The current trial status is completed. This product is registered under clinical trial identifier NCT00694460. Target conditions include Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00694460 | Phase 2 | Completed |
Competing Products
20 competing products in Rabies